Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEMVAC in Early Stage Triple Negative Breast Cancer
NCT05455658Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Nov 2022
- Primary completion
- Jun 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of STEMVAC in triple-negative breast cancer (TNBC), sponsored by University of Washington. Started Nov 2022; status: active, not recruiting.
02
Drugs
STEMVAC
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05455658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05455658.